ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 664

Low Vitamin D Is Associated with Thrombosis in Systemic Lupus Erythematosus

Michelle Petri1, Wei Fu2 and Daniel Goldman2, 1Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, 2Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: systemic lupus erythematosus (SLE) and thrombosis, Vitamin D

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster I: Biomarkers and Outcomes

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Low vitamin D is common in systemic lupus erythematosus (SLE). It is also found in antiphospholipid syndrome. Vitamin D has effects on tissue factor, PAI-1, thrombomodulin and platelet aggregation that suggest it has an anti-thrombotic role. We asked whether low vitamin D was associated with thrombosis in SLE, adjusting for lupus anticoagulant.

Methods: A total of 1,392 SLE patients were included in the analysis. At the first visit when vitamin D was measured, 76.7% had levels of 25-hydroxyvitamin D <40 ng/mL. The SLE patients were: 92% female, mean age 42.9 years, and ethnicity 50% Caucasian, 41% African American. 27% patients had a history of thrombosis; 7% stroke, 4% MI and 14% DVT.

Results: Vitamin D, measured either as a continuous variable or as “low” (<40 ng/mL) vs. normal, was associated with any thrombosis and with DVT.

Table 1: Associations of First Vitamin D Measurement with Thrombosis

Positive for Thrombotic Event

No Thrombotic Event

P-value

Mean (SD)

N (%)

Mean (SD)

N (%)

Any Thrombotic Event

Vitamin D (ng/ml) (Mean/SD)

27.6(15.1)

30.6(14.6)

0.0008

Vitamin D < 40 ng/ml (N/ %)

299(80.4)

759(75.4)

0.064

Stroke

Vitamin D (ng/ml) (Mean/SD)

28.9(15.2)

29.9(14.7)

0.5408

Vitamin D < 40 ng/ml (N/ %)

79(75.2)

988(76.9)

0.7914

Myocardial Infarction (MI)

Mean (SD)

N (%)

Mean (SD)

N (%)

Vitamin D (ng/ml) (Mean/SD)

30.2(16.9)

29.8(14.7)

0.883

Vitamin D < 40 ng/ml (N/ %)

35(70)

1032(77)

0.3258

DVT

Mean (SD)

N (%)

Mean (SD)

N (%)

Vitamin D (ng/ml) (Mean/SD)

25.9(13.4)

30.4(14.9)

<0.0001

Vitamin D < 40 ng/ml (N/ %)

171(87.2)

895(75)

0.0002

We next adjusted for race, age, sex and lupus anticoagulant. Low vitamin D remained associated with DVT.

Table 2 Summary of Adjusted Odds Ratio for Low Vitamin D (< 40 ng/ml)

Dependent Variables

Unadjusted OR (95% CI)

Adjusted OR (95% CI)

Any Thrombosis

1.33 (0.99,1.79)

1.36 (0.99,1.86)

Stroke

0.91 (0.58,1.45)

0.92 (0.57,1.48)

MI

0.7 (0.38,1.29)

0.8 (0.42,1.53)

DVT

2.28 (1.47,3.54)

2.31 (1.47,3.65)

We next looked prospectively: this analysis excluded thrombotic events before the first vitamin D measurement. It allowed for vitamin D to be a time-varying variable, as replacement therapy was given if it was low. After adjustment for race, age and sex, the adjusted hazard ratio remained significant for any thrombosis: 1.75 (1.04,2.92).

Conclusion: Low vitamin D was significantly associated with any thrombosis and with DVT (even after adjustment for lupus anticoagulant). In prospective models it remained significantly associated with any thrombosis. As supplementation with vitamin D was proven to reduce thrombosis in an oncology randomized clinical trial, vitamin D replacement should become routine in SLE patients at risk for thrombosis.


Disclosure: M. Petri, Anthera Inc, 5,GlaxoSmithKline, 5,EMD Serono, 5,Eli Lilly and Company, 5,Bristol Meyer Squibb, 5,Amgen, 5,United Rheumatology, 5,Global Academy, 5,Exagen, 2; W. Fu, None; D. Goldman, None.

To cite this abstract in AMA style:

Petri M, Fu W, Goldman D. Low Vitamin D Is Associated with Thrombosis in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/low-vitamin-d-is-associated-with-thrombosis-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-vitamin-d-is-associated-with-thrombosis-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology